TRISALUS LIFE SCIENCES INC
TLSI · NASDAQ
Updated at 2026-10-14 09:06:44
- Today's High
- $4.12
- Today’s Low
- $3.94
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $4.10
- Previous Close
- $4.14
- Volume
- 78.52K
- Market Cap
- $254.91M
- P/E Ratio
- --
- EPS
- $-0.58
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- MEDICAL DEVICES
- Headquarters
- 6272 WEST 91ST AVENUE, WESTMINSTER, CO, UNITED STATES, 80031
- Country
- US
- Listing Date
- 2020-12-18
- Fiscal Year End
- December
- Shares Outstanding
- 61.42M
- CIK
- 0001826667
- Website
- trisaluslifesci.com
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical firm at the forefront of enhancing cancer therapy through its proprietary localized drug delivery systems, which significantly improve the effectiveness of immuno-oncology agents. The company is strategically addressing the complexities of tumor microenvironments with a robust pipeline of clinical programs aimed at advancing treatment options in oncology. With a commitment to expanding patient access to transformative therapies, TriSalus is well-positioned to drive meaningful change in cancer care, aligning with the growing demand for advanced, effective cancer treatments. The company’s initiatives underscore its potential to be a key player in the rapidly evolving oncology landscape, attracting interest from both investors and healthcare stakeholders.
Financial Metrics
Revenue
2026-06-30
$11.4M
2026-03-31
$8.89M
2025-12-31
$13.2M
2025-09-30
$11.56M
Operating Expenses
2026-06-30
$19.71M
2026-03-31
$16.08M
2025-12-31
$14.71M
2025-09-30
$18.67M
Net Income
2026-06-30
-$9.18M
2026-03-31
$1.53M
2025-12-31
-$9.75M
2025-09-30
-$10.81M
Net Profit Margin
2026-06-30
-80.53%
2026-03-31
17.29%
2025-12-31
-73.85%
2025-09-30
-93.47%
Earnings Per Share
2026-06-30
$-0.16
2026-03-31
$0.02
2025-12-31
$-0.05
2025-09-30
$-0.87
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$7.42M
2026-03-31
$3.11M
2025-12-31
-$8.17M
2025-09-30
-$9.18M
Effective Tax Rate
2026-06-30
-0.04%
2026-03-31
0.25%
2025-12-31
0.14%
2025-09-30
-0.04%
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $11.4M | $8.89M | $13.2M | $11.56M |
| Operating Expenses | $19.71M | $16.08M | $14.71M | $18.67M |
| Net Income | -$9.18M | $1.53M | -$9.75M | -$10.81M |
| Net Profit Margin | -80.53% | 17.29% | -73.85% | -93.47% |
| Earnings Per Share | $-0.16 | $0.02 | $-0.05 | $-0.87 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$7.42M | $3.11M | -$8.17M | -$9.18M |
| Effective Tax Rate | -0.04% | 0.25% | 0.14% | -0.04% |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.